Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 4/20 | 0.42 |
| ▸ | HTR2A | P28223 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | SRC | P12931 | 4/20 | 0.39 |
| ▸ | BRAF | P15056 | 3/20 | 0.38 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | BCL6 | P41182 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30879562 | 1.00 | HTR2C (0.42) | HTR2CHTR2AL3MBTL1SRCBRAF | |
| SCHEMBL30879557 | 1.00 | HTR2C (0.42) | HTR2CHTR2AL3MBTL1SRCBRAF | |
| SCHEMBL27430647 | 0.91 | HRH4 (0.41) | HTR2CHTR2AL3MBTL1SRCBRAF | |
| SCHEMBL27430744 | 0.91 | HRH4 (0.41) | HTR2CHTR2AL3MBTL1SRCBRAF | |
| SCHEMBL27430721 | 0.91 | HRH4 (0.41) | HTR2CHTR2AL3MBTL1SRCBRAF | |
| SCHEMBL27430646 | 0.91 | HRH4 (0.41) | HTR2CHTR2AL3MBTL1SRCBRAF | |
| SCHEMBL27429805 | 0.91 | HRH4 (0.41) | HTR2CHTR2AL3MBTL1SRCBRAF | |
| SCHEMBL27430722 | 0.82 | HTR2C (0.44) | HTR2CHTR2AL3MBTL1SRCHRH4 | |
| SCHEMBL27429710 | 0.79 | HTR2C (0.64) | HTR2CHTR2ASRCHRH4 | |
| SCHEMBL27248330 | 0.78 | L3MBTL1 (0.58) | HTR2CHTR2AL3MBTL1SRCHRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240199624-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | CHDI FOUNDATION INC (US) | 2024-06-20 | — | — | US | disclosed |
| WO-2024118607-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | CHDI FOUNDATION, INC. (US) | 2024-06-06 | — | — | WO | disclosed |
| WO-2024118607-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | CHDI FOUNDATION, INC. (US) | 2024-06-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199624-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | MSH2, KRAS, CHAMP1 | HTR2C 3424/4885HTR2A 3918/4885L3MBTL1 1129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.